AMSTERDAM – The contraceptive pill is the best known and also the most used contraceptive in the Netherlands and Belgium(1,2). However, many women are thinking about switching to another method, especially women currently using birth control pill.(3) This is evident from a study that healthcare company Organon has commissioned among 2,000 women by research agency IPSOS.
When it comes to contraceptive methods (and other types of protection) the methods to choose from are increasing, but most women between the ages of 18 and 44 in Belgium and the Netherlands mainly use oral contraception, followed by the condom.(2) The IPSOS study shows that 4 out of 10 women consider using another contraception method in the future, especially women who are currently using the contraceptive pill.3) These women prefer long-acting reversible contraception, according to the majority of women in question.(4)
A method that was the best solution at the initial stage no longer has to be the way a few years later. In an issue of Topic Talks gynecologist and director of Ellesie, Els van Doorn, emphasizes that continuing on autopilot is not always the best way to go. “Investigate together with your healthcare provider whether your contraceptive method is still the right one. Many women don’t think about it enough, but with the right birth control you can improve your quality of life and feel happier. (5)
“In the choice (of contraception), the woman is leading,” emphasizes gynecologist Annette ter Haar, also in Topic Talks. “Some women are opposed to oral contraception but open to other forms of birth control.” (6)
It is important that women receive sufficient and correct information to be able to make their choice properly. They can always contact a healthcare professional: women in the Netherlands and Belgium usually select a contraceptive method after consultation with their general practitioner (especially in the Netherlands) or gynecologist (in Belgium). (7) In addition, information from independent websites can be useful in decision making, such as:
OSS – Organon is going to significantly expand the production of long-acting contraception in the Netherlands again. The name Organon officially returned last year and since then the company has entered into various collaborations and acquisitions worldwide to expand its portfolio of medicines and other health solutions. In order to be able to meet the promise that the company made at the start last year: improving the health of women. This is followed by substantial investments in Organon’s largest production site in the world, in Oss.
At the start of Organon in June 2021, it was already clear that the ‘birthplace’ Oss will continue to play an important role in the new company. In Oss, Organon has a rich history in the production of contraception, high-quality innovative technology and a huge distribution network for reliable and continuous delivery to 140 countries in the world. 1,150 of Organon’s more than 9,000 employees worldwide work here. The production facility in Oss is the largest of the six worldwide and will expand again.
In 2021, a new robot production line for assembly and packaging of contraceptive rods was already put into operation. There is approval now to invest in another robot production line, but also for other innovations. Wenny Raaijmakers (Plant Manager Organon Oss, location director) explains: “The intention is to start using this line within three years. Organon Oss is also investing in new extrusion machines with which the contraceptive rods are made and which will increase the supply to the robot lines.”
Volumes “We are also going to invest in an extra automated packaging line with which the end product is packed in a box with leaflet. After that, the end product can be delivered to doctors and pharmacists worldwide,” says Wenny Raaijmakers. “And in order to cope with the larger production volumes, logistics routes in the production building are also being adapted and systems for IT and quality control are being improved.” In order to make room in the current building (behind the now well-known mural) for expansion of the production of the contraceptive rod, the production of the contraceptive ring will be concentrated in the relatively new building ‘CP’. Wenny: “With an ongoing investment, two modernized machine lines will be located there. All these improvement programs and investments contribute to deliver on the promise of women’s health in the short and long term.” Altogether, Organon is investing approximately 40 million euros in expanding production in Oss.
The production facility in Oss is the only location in the world where Organon produces contraceptives. From this location, a dedicated team also works specifically on the guidance and logistics for family planning, especially in Africa and Asia. The use of a product such as the pill is less obvious in these countries. Long-acting contraception may be a solution for women in remote areas who often have to walk for hours to the nearest clinic. Good contacts with global organizations such as the Bill & Melinda Gates Foundation and the World Health Organization (WHO) have been playing an important role for many years in making long-acting contraception more available, especially in Africa, Latin America and Asia.
At the start in June 2021, Organon made a promise: listening to women worldwide to better understand their health needs and identify solutions that are urgently needed. Petra Willems, Managing Director of Organon Benelux: “There is a need to address diseases and conditions that only or disproportionately impact women. Our impact will go beyond medicine, contraception and fertility treatments. We know we can do so much more for women and their health. “
OSS – International Women’s Day got a festive touch yesterday at Organon in Oss with the official opening of the new atrium. A glass building that functions as an inviting entrance but above all as a connecting link. A place where people can come to meet each other. The project was therefore aptly named ‘Agora’, in Ancient Greece the central place where social, political and commercial life took place.
The new atrium fits in with everything with the new Organon: open, modern and focused on meeting and collaborating. Ina Adema (King’s Commissioner in North Brabant) performed the official opening in the presence of, among others, Mayor Wobine Buijs-Glaudemans, Wenny Raaijmakers (site director Organon Oss) and Petra Willems (Managing Director Organon Benelux).
The construction was announced a few years ago (then still under the flag of MSD). First, outdated office and meeting rooms were replaced by a new warehouse. Subsequently, the Oss site had to deal with the spin-off of MSD and the building had to be done in an eventful time that was dominated by corona. But the result is impressive! After the mural on the well-known blue wall, the glass atrium now also gives a new face to Organon’s largest production site in the world.
Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on March 8 as a day to recognize the growing health disparities women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognizes the need for a global effort to address her health and is starting with its own employees by providing paid time off this year to attend to their own health needs.
Research shows that the corona crisis is hitting women harder than men. In addition to unemployment and poverty, women are also more burdened privately by crisis and the measures taken, conclude HealthyWomen and the Dutch SER after research by, among others, McKinsey. In a survey, 78% of women said they usually put their own healthcare needs, such as scheduling doctor’s appointments, aside to focus on taking care of their family and other priorities.
“Organon launched with a commitment to listen to the needs of women and as part of our research, we learned that women are finding it harder than ever to make the time to care for even their most basic health needs,” said Kevin Ali, chief executive officer, Organon. “As a company investing in innovation to improve women’s health, I felt a responsibility to address this within our own global community of almost 9,500 employees.
”Petra Willems, Managing Director Organon Benelux, adds: “This year, the symbolic action we are taking is to encourage all our employees (men and women) to spend a day off to make a commitment to their own health and/or the health of the women in their lives. Whether that’s thinking about how you can improve your health or relaxing for a day. This includes more than 2,000 employees of Organon at the production sites and offices in the Benelux countries.”
By improving the understanding of women’s health needs, we are one step closer to eliminating the inequity gap. Organon invites organizations in The Netherlands, Belgium and Luxembourg and across the globe to join in raising awareness of the inequity in women’s health and to adopt initiatives that help women prioritize their health.
AMSTERDAM – Healthcare company Organon will collaborate in the Netherlands with Titus Health Care, which supports gynecologists, obstetricians, abortion doctors and general practitioners in providing optimal contraceptive care. Both companies have the ambition to make a difference in women’s health. One of the spearheads is to offer them optimal freedom of choice in the field of contraceptive methods.
At its launch in June 2021, Organon launched a commitment: to listen to women worldwide, to understand ‘her’ health needs and help identify solutions that are urgently needed. “Because there is a need to address diseases and conditions that only or disproportionately impact women”, says Petra Willems, Managing Director of Organon Benelux. “Our impact will go beyond medicine, contraception and fertility treatments. Because we know that we can do so much more for women and their health. That is why we are proud that we have been able to realize a strategic partnership in the Benelux so quickly.”
A lot of experience Establishing close collaboration with external partners is a key tenet in the Organon strategy, whether it is to develop new therapies or to give more women access to existing products. The partnership with the Dutch company Titus Health Care is an excellent example of this. Freek Hendriksen, who is responsible for Alliance & Business Development within the management team of Organon Benelux, says: “The Titus Health Care team is very experienced in training healthcare professionals and has a large network and a strong reputation in healthcare. Its entrepreneurial culture and mindset are also an excellent fit with Organon’s.”
Join forces Together, the companies will work on improving awareness of and access to long-acting contraceptive methods. “Every woman is unique and that requires tailormade contraceptive advice. That is why Titus Health Care and Organon are joining forces. We share the ambition to contribute to the education of healthcare providers so that they can give women appropriate advice about contraception,” says Judith Wiegant, Managing Director of Titus Health Care. “We are joining forces with a broad portfolio of hormonal and non-hormonal contraception”, adds the company’s founder and co-director Joep de Mönnink. “To offer women optimal freedom of choice.”
On 1 March 2022, the construction of Grizzly, a large and sustainable building on the Osse life sciences campus Pivot Park, will start. With an area of 11,000 m² spread over eight floors, Grizzly will act as a multi-tenant building. Organon is one of the first five tenants, along with Acerta Pharma, ImmunoPrecise Antibodies, NTRC and Oncolines.
Brigitte Drees, director of Pivot Park, is very happy that the construction of Grizzly can start. “The fact that we can start is mainly due to the five tenants. It’s great to see that they have every confidence in our plans and ambitions. All of these companies are already located at Pivot Park, but need more space than they currently have.” If construction goes according to plan, Organon and the other tenants will be able to move into the building from October 2023. Upon completion, Grizzly (which is a working name) will also get its final name.
JERSEY CITY – Organon (NYSE: OGN) today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health.
Forendo, based in Finland, is pioneering the translation of intracrinology science into first-in-class therapeutic solutions. Intracrinology enables physicians to address diseases on an unprecedented tissue-specific level. Forendo’s programs are targeting endometriosis and polycystic ovarian syndrome (PCOS).
“Organon is dedicated to delivering medically significant women’s healthcare interventions, prioritizing disease areas based on her unmet needs. Endometriosis is among our highest priority areas of focus,” said Kevin Ali, Organon’s Chief Executive Officer. “Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.”
Organon earlier announced the acquisition of Alydia Health (that focuses on postpartum hemorrhage, PPH) and the fact that Organon and ObsEva are entering an agreement whereby Organon will license the global development, manufacturing and commercial rights to a potential treatment for preterm labor.
OSS – Almost one hundred years ago, in 1923, Salomon (Saal) van Zwanenberg founded NV Organon in the town of Oss in the Dutch province of North Brabant. Organon was the first company in Europe to market a substance as an effective medicine for treating diabetes. Over the years, an extensive selection of hormone-based drugs followed, including the contraceptive pill, introduced in 1962, which is probably the best known. Thanks to this product, Organon became a world player in the pharmaceutical industry and an important economic driver for the region.
As you walk through the grounds at Organon’s site almost a century later, you still see much that reminds you of the company’s former glory, in addition to new buildings. That tradition is often just skin-deep: hyper-modern laboratories and production facilities nestle behind the dark brown brick façades and stained-glass windows. Wenny Raaijmakers, the current site manager of Organon Oss, is proud of the organization’s rich legacy. “But the new Organon really is a very different company,” she says.
AMSTERDAM – On November 9 Organon officially opened its offices in Amsterdam. Together with guest of honor Clémence Ross-van Dorp, ambassador for the Dutch Life Sciences & Health sector, Benelux managing director Petra Willems marked the occasion by cutting a ribbon. The Amsterdam offices will be home to a diverse group of colleagues, comprising the Benelux commercial organization, Supply Chain Management, and a substantial number of colleagues in regional and global roles. All in all, these offices will be home to more than 100 colleagues representing more than 25 nationalities.
Petra Willems pointed out the immense contribution of the teams over the past months. “These offices will be where we all belong, and where we can rise together to meet the needs of women around the world.” The importance of ‘rising together’ was echoed by Clémence Ross-van Dorp, who acknowledged the important historical role of Organon in women’s health, as well as in the development of the Life Sciences sector in The Netherlands. She also emphasized the vast amount of work that is still needed to improve the lives of women around the world.
OSS – Soon it will be 100 years ago that the first medicines were made in Oss. A milestone that we are proud of and that we celebrate with a theme year: #100yearspharmafuture (September 2022 to October 2023). The initiative comes from Aspen Oss, MSD Nederland, Life Sciences campus Pivot Park, the municipality of Oss and Organon.
The preparations have started and the first plans are on the table. The initiative group is still looking for cooperation with companies and organizations. Do you have ideas for the theme year? Send an email to firstname.lastname@example.org
With Organon, we were at the cradle of the pharmaceutical sector in the Netherlands, with groundbreaking discoveries such as insulin and the contraceptive pill. The companies are still strongly connected by the joint past. From the very first research to the large-scale commercial production of medicines.
“Every company in our cluster does work that matters”, says Wenny Raaijmakers of Organon. “After the anniversary year, no one doubts it: Oss is the pharmaceutical capital of the Netherlands”, according to Mayor Wobine Buijs-Glaudemans.
This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.